Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics
MNMD Price/Volume Stats
| Current price | $8.52 | 52-week high | $12.22 |
| Prev. close | $8.52 | 52-week low | $2.41 |
| Day low | $8.36 | Volume | 359,924 |
| Day high | $8.76 | Avg. volume | 1,884,392 |
| 50-day MA | $8.37 | Dividend yield | N/A |
| 200-day MA | $4.82 | Market Cap | 598.68M |
MNMD Stock Price Chart Interactive Chart >
Mind Medicine (MindMed) Inc. (MNMD) Company Bio
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest MNMD News From Around the Web
Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.
Weekly Roundup on the Cannabis Sector & Psychedelic SectorKey Takeaways; Cannabis Sector • Canopy Growth implemented share consolidation to meet Nasdaq listing standards. • Curaleaf successfully listed on the Toronto Stock Exchange. • Safe Harbor Financial boosted social equity in Connecticut with a $1.17m loan to Higher Collective. Key Takeaways; Psychedelic Sector • Awakn achieved significant regulatory milestone and closed financing tranche as […] |
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety DisorderNEW YORK, December 14, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-depend |
GH Research Drags Down Psychedelic Drug Stocks Index By 7%The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. |
MindMed Reports Third Quarter 2023 Financial Results and Business HighlightsNEW YORK, November 02, 2023--MindMed today reported its financial results for the quarter ended September 30, 2023. |
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateNEW YORK, October 26, 2023--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET. |
MNMD Price Returns
| 1-mo | -10.32% |
| 3-mo | 130.89% |
| 6-mo | 244.94% |
| 1-year | 129.03% |
| 3-year | -85.87% |
| 5-year | N/A |
| YTD | 132.79% |
| 2023 | 66.36% |
| 2022 | -89.37% |
| 2021 | -54.75% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...